Pilot Project

试点项目部分旨在为开发和探索新的 研究活动或方向，以及可以发展为独立资助研究的独特机会 项目在6-10年期间，我们建议每年资助两个试点项目，预算约为50，000美元 每个项目。这些项目的预期期限为1年;项目可延长至两年 成功的竞争性更新。中心科学总监将管理该组件。试点 项目申请将征求每年从EGCRC和UCSF的研究人员。每项提案将 评估的科学价值，创新，并为相关的中心的总体目标，至少有两个 ACTG计划顾问委员会成员、科学主任和中心主任。 资助建议将由中心指导委员会审议批准。两个试点 项目已经提出，并授予06年的资金。项目7A（A）。Kayser，主任）将 研究δ阿片受体（DOR）激动剂ALK 33是否可以成为治疗酒精的潜在药物 摄入量和渴望的研究。在人类受试者中进行的实验也旨在进行 功能磁共振成像研究，以确定是否增加内侧前额叶皮层和 与奖励和焦虑相关的大脑区域。

The Pilot Project Component is designed to provide a flexible means for developing and exploring new research activities or directions, and unique opportunities that can evolve into independently funded research projects. During Years 6-10 we propose funding two pilot projects per year with a budget of about $50,000 per project. The expected duration of these projects will be 1 year; projects can be extended to two years upon successful competitive renewal. The Center Scientific Director will manage this Component. Pilot Project applications will be solicited annually from EGCRC and UCSF investigators. Each proposal will be evaluated for scientific merit, innovation, and for relatedness to the Center's overall goals by at least two members of the ACTG Program Advisory Board, the Scientific Director, and the Center Director. Recommendations for funding will be considered for approval by the Center Steering Committee. Two Pilot Projects have been proposed and awarded funding for Year 06.Project 7A (A. Kayser, Director) will examine whether the Delta Opioid Receptor (DOR) agonist, ALK33, can be a potential drug to treat alcohol intake and craving in a preclinical human trial. Experiments in human subjects are also aimed to conducted fMRI studies to determine whether the increase the connectivity between the medial prefrontal cortex and brain regions associated with reward and anxiety.